Powered by Lexis+®
Jurisdiction(s):
United Kingdom
CASE STUDY

“In some areas of research there were also significant time savings. You get to what you are looking for more quickly, which all goes to the value of the product.”

Harper Mcleod

Access all documents on Half life

Half life meaning

Published by a LexisNexis Energy expert
What does Half life mean?
In legal practice on radiation, environment and health and safety, half-life describes how long it takes for a radionuclide’s activity to reduce to 50% of its initial level (that is, when roughly half of its atoms have decayed). The term is a scientific expression used across multiple legal contexts rather than a statutory definition; regulators and courts generally adopt its ordinary technical meaning, reflected in IAEA and UK/Irish regulatory guidance. Half-life is central to hazard assessment, dose modelling and the classification of radioactive waste (short-lived versus long-lived). It informs environmental permitting/authorisations for keeping, using and disposing of radioactive substances, including setting activity limits, storage and decay-in-storage periods, monitoring requirements and clearance/ exemption considerations. It is also relevant to nuclear site licensing and decommissioning strategies, contaminated land remediation timeframes, and the transport of radioactive materials. In healthcare, it underpins controls on medical radionuclides and associated waste management. Usage and significance are broadly consistent across England and Wales, Scotland, Northern Ireland and Ireland, under ionising radiation worker-protection regimes and radioactive substances/environmental permitting frameworks administered by the UK environment agencies and the Irish Environmental Protection Agency.
Speed up all aspects of your legal work with tools that help you to work faster and smarter. Win cases, close deals and grow your business–all whilst saving time and reducing risk.

View the related News about Half life

NEWS
UK Immigration Case Law Update Jan–July 2024: Sponsor Licence Revocations, Article 8 Limbo, Judicial Fairness, EUSS/Withdrawal Agreement, GPS Tagging, Deportation, Citizenship Deprivation and Nationality

Sponsor licence revocation challenges: no need for a global assessment During the first half of 2024, the Administrative Court has delivered a series of inconsistent rulings on whether the Secretary of State for the Home Department (SSHD) must undertake a global assessment when deciding to revoke a sponsor licence. All the claims have featured care providers running care homes who have brought challenges to revocation decisions taken by the SSHD. In R (Supporting Care Ltd) v SSHD [2024] EWHC 68 (Admin) (19 January 2024), His Honour Judge Siddique quashed the SSHD’s decision on the single basis that he had ‘failed to conduct an adequately reasoned global assessment of all relevant considerations in deciding whether to revoke or downgrade the sponsor licence.’ (para [55]). The dispute concerned entirely the necessity for such holistic evaluation in sponsor licence revocation decision-making by the SSHD...

Read More Right Arrow
NEWS
IFS urges UK government: four-point state pension guarantee, extended automatic enrolment (16-74), targeted contribution increases and pot consolidation to deliver sustainable, adequate retirement incomes

The IFS outlined several policy proposals in a report that it said would address the current challenges facing the UK pensions system and help to solve the problems future generations of retirees might face Produced with the abrdn Financial Fairness Trust, the study urges an overhaul of the UK state pension alongside steps to lift private pension saving and improve means-tested help for low-paid workers. It also recommends stronger guidance so people can steward their assets through retirement. Paul Johnson, the IFS Director and co-author, noted there is 'much to celebrate' about the pensions landscape, yet cautioned that policymakers risk complacency. He warned: 'Without decisive action, too many of today's working-age population face lower living standards and greater financial insecurity through their retirement'. Over two-and-a-half years, the review identified priorities to safeguard savers’ futures, from rising pressures on public finances as the population ages to the widespread shortfall in saving that leaves many without an adequate income in later life...

Read More Right Arrow
NEWS
EU law weekly: competition, corporate sustainability, data/AI, financial services, environment, IP, life sciences, TMT and trade - key developments, 3 April 2025

In this issue: EU fundamentals Competition and state aid Corporate Data protection and cybersecurity Free movement, immigration and employment Financial services Environment Insurance and reinsurance IP Life sciences Regulatory TMT International trade Daily and weekly news alerts Trackers EU fundamentals Commission issues formal notices to EU Member States for failing to transpose EU directives The European Commission has dispatched letters of formal notice to several EU Member States that have not implemented five directives into national law. These measures span electricity market design (26 Member States), building energy performance (9 Member States), digital operational resilience (13 Member States), road transport social legislation (16 Member States), and food extraction solvents (5 Member States). Member States have two months to reply and finalise transposition of the directives, whose deadlines fell between January and February 2025. Denmark alone has fully transposed the Electricity Market Directive within the required timeframe. See: LNB...

Read More Right Arrow

View the related Practice Notes about Half life

PRACTICE NOTES
Contentious probate in England and Wales: capacity, undue influence, 1975 Act, proprietary estoppel and mutual wills; caveats and ADR—case study of later-life will change in a second marriage

Facts Kevin (69) and Amelia (60) have been married for three decades. This is Kevin’s second marriage; he has two adult children, Barbara and Tom, from a first marriage that ended acrimoniously. Barbara and Tom put up with their step-mother but have never truly liked her, as she and Kevin were friends before his split from their mother. Amelia is very fond of her step-grandchildren. Together, Kevin and Amelia run a thriving property investment business, and the bulk of their wealth has been created during the marriage. Although Amelia’s contribution has been equal—some would say greater—most assets sit in Kevin’s name. Over the years, he has often told Amelia that half of everything he owns is hers. In 2010, they agreed that whoever died first would leave their estate to the other, and that the survivor would then leave their estate to Barbara and Tom, subject to some modest legacies. As Amelia has no close blood relatives, she has been comfortable with this arrangement...

Read More Right Arrow
PRACTICE NOTES
Personalised and precision medicine in the UK: technologies, ethics, data protection, and regulatory landscape for genomics, AI, DTC testing, pharmacogenomics, NIPT, CRISPR, mRNA immunotherapies, companion diagnostics, and market outlook

What is personalised medicine Personalised medicine has been part of clinical practice for quite some time. Clinicians have, to differing degrees, tailored care to individual patients using information gathered about them. Over the last decade and a half, however, the emergence of systems biology has markedly broadened its scope; in contemporary practice it depends on collecting as much data as possible about a specific biological system under study. The aim is to interpret these collected datasets in ways that enhance understanding of a living system and its pathologies, ultimately enabling targeted interventions that are responsive to an individual patient or to groups of patients. It is often characterised as care that is ‘custom‑made’, set against the more traditional, ‘one size fits all’ model. Although many cell therapies, gene therapies and other advanced therapy medicinal products (ATMPs) are regarded as personalised medicines, the domain is wider and encompasses every step of the medical process, from start to finish, beginning with diagnosis—frequently molecular diagnosis using biomarkers—and concluding with targeted medicinal treatments...

Read More Right Arrow
PRACTICE NOTES
PFAS in the UK: regulatory controls, compliance obligations, enforcement and liabilities under REACH, POPs, CLP, water and waste; developments, contaminated land, transactions and insurance

What are PFAS? Perfluoroalkyl and polyfluoroalkyl substances are man‑made chemicals found across industry and everyday items. Key uses span: aerospace and defence automotive and aviation food contact materials and processing textiles, leather and apparel for waterproofing and stain resistance construction materials metal plating and metal products household products, such as non-stick cookware ski wax electronics and semi-conductors cosmetics firefighting foams medical devices PFAS consist of carbon and fluorine; this exceptionally strong bond prevents environmental breakdown. Scientists have yet to determine a half-life for PFAS, earning them the label ‘forever chemicals’. What are the risks posed by PFAS? PFAS may enter the environment at nearly every point in a product’s lifecycle. They can migrate from packaging or products into prepared food, be washed off by rainwater, or be shed during normal use. PFAS are also directly sprayed into the environment...

Read More Right Arrow